Daily Respiratory Research Analysis
Analyzed 146 papers and selected 3 impactful papers.
Summary
Three standout respiratory studies span basic virology, pandemic preparedness, and fibrosis therapeutics. Mechanistic mapping shows RSV viral factories arise via liquid–liquid phase separation tuned by N, P, M2-1, and RNA, revealing targetable assembly rules. A global H5 avian influenza synthesis integrates phylodynamics and epidemiology to clarify clade-specific zoonotic risks, while a macrophage Kynurenine–AhR–SLC39A10–Zn2+ axis emerges as an endogenous brake on pulmonary fibrosis with therapeutic potential.
Research Themes
- Viral condensates and liquid–liquid phase separation as antiviral targets
- Phylodynamics and zoonotic risk modeling in avian influenza A(H5)
- Immunometabolism in pulmonary fibrosis (Kynurenine–AhR–Zn2+ axis)
Selected Articles
1. In vitro liquid-liquid phase separation induced by respiratory syncytial virus proteins and RNA.
Using PhaseScan with complementary biochemical and cellular assays, the authors map RSV condensate assembly rules: oligomeric N and P tetramers are necessary and sufficient for LLPS in vitro, monomeric N antagonizes LLPS, and M2-1 enhances condensate formation via multivalency while preferentially binding 5′-capped RNA. These determinants explain viral factory subcompartmentalization and reveal LLPS as a tractable antiviral target.
Impact: Defines molecular stoichiometry and RNA selectivity underpinning RSV viral factory assembly, enabling rational design of LLPS-disrupting antivirals.
Clinical Implications: Identifies LLPS interfaces (N–P stoichiometry and M2-1–capped RNA binding) as potential druggable nodes for RSV; informs assays to screen small molecules that modulate condensate material properties.
Key Findings
- Condensate formation in vitro occurs without crowding agents at optimal concentrations of oligomeric N and P tetramers.
- Monomeric N inhibits LLPS, while M2-1 enhances condensate formation by increasing multivalency.
- M2-1 preferentially binds 5′-capped RNA, whereas N binds uncapped RNA, implying functional subcompartmentalization within viral factories.
Methodological Strengths
- High-throughput microfluidic PhaseScan to map LLPS phase behavior across concentration space
- Orthogonal validation with biochemical and cellular assays to link in vitro LLPS to cellular condensates
Limitations
- Predominantly in vitro work; lacks in vivo validation that LLPS-disrupting interventions reduce RSV replication in animals.
- Quantitative kinetics of assembly/disassembly and host-factor contributions were not fully delineated.
Future Directions: Test small molecules or peptides that disrupt N–P or M2-1–RNA interactions in cell and animal RSV models; define host co-factors and biophysical maturation of RSV factories in vivo.
Respiratory syncytial virus (RSV) causes severe respiratory infections, with viral replication occurring in cytoplasmic membraneless viral factories formed by liquid-liquid phase separation (LLPS). The interactions among the RSV nucleoprotein N, phosphoprotein P, transcription factor M2-1, and RNA drive these condensates. Here, we used a microfluidic PhaseScan platform, together with biochemical and cellular assays, to systematically characterize LLPS involving RSV proteins and RNA. We identified optimal concentrations of oligomeric N and P tetramers for condensate formation in vitro without crowding agents, demonstrated that monomeric N inhibits LLPS and revealed that M2-1 enhances condensate formation by increasing multivalency. Notably, we found that M2-1 preferentially binds 5' capped RNA, distinguishing it from N, which binds uncapped RNA. These findings elucidate molecular determinants of RSV viral factory assembly and subcompartmentalization, providing insights into viral replication mechanisms and informing potential antiviral strategies targeting LLPS processes.
2. Human infections with avian influenza A(H5) viruses with potential pandemic risk: 1997-2025.
Integrating 7,445 HA sequences with epidemiologic data and mechanistic modeling, the study reveals geographically distinct clade succession of H5 viruses and clade-specific heterogeneity in human case demographics and exposure sources. Findings sharpen zoonotic risk assessment and underscore the need for continuous, clade-aware genomic surveillance and preparedness.
Impact: Defines clade- and region-specific dynamics of H5 emergence at the animal–human interface, informing risk-based surveillance, vaccination strain selection, and outbreak readiness.
Clinical Implications: Supports targeted surveillance and tailored countermeasures (PPE, diagnostics, vaccination strategies) based on clade prevalence and exposure patterns; aids risk communication for high-exposure groups.
Key Findings
- Phylodynamic analysis of 7,445 HA sequences shows frequent, region-specific succession of H5 clades since 1997.
- Among 1,104 human H5 cases, age, sex, and exposure sources differed by subtype and clade, indicating heterogeneous zoonotic interfaces.
- Mechanistic models integrating genetics and epidemiology delineate spread patterns that can guide surveillance and response.
Methodological Strengths
- Large-scale integration of genomic surveillance (7,445 HA sequences) with epidemiologic case data (1,104 cases)
- Mechanistic modeling to infer spread and zoonotic interface heterogeneity across regions and clades
Limitations
- Surveillance and reporting biases likely affect case detection and sequence representativeness across regions.
- Incomplete clinical metadata may limit precise severity or transmission potential estimates by clade.
Future Directions: Expand real-time, clade-resolved genomic surveillance and link to standardized clinical/ exposure metadata; evaluate vaccine/antiviral effectiveness against emergent clades.
Highly pathogenic avian influenza (HPAI) A(H5) viruses have caused sporadic human infections since 1997, with recent detections in the Americas and Asia. However, the evolutionary dynamics of different HPAI A(H5) viruses at the animal-human interface, along with their associated disease severity, propensity for animal-to-human (zoonotic) spillover, and human-to-human transmission potential, remain unclear. Here, we combine available genetic and epidemiological data with mechanistic models to better understand the global spread of HPAI A(H5) viruses that spilled over to humans in 1997-2025. Analysis of 7445 subsampled hemagglutinin gene sequences revealed frequent regional succession of HPAI A(H5) virus clades that varied by geographic location. The 1104 reported human HPAI A(H5) cases exhibited subtype- and clade-specific heterogeneity in age, gender, and exposure sources (
3. Kynurenine-AhR-SLC39A10-Zn
Serum Kynurenine, tryptophan, and KTR are elevated in PF and inversely correlate with lung function, yet Kyn acts protectively: macrophage Ido1 or AhR deletion worsens fibrosis, while exogenous Kyn attenuates it. Mechanistically, Kyn activates AhR to upregulate Slc39a10, boosting Zn2+ influx and restraining profibrotic macrophage polarization; combining Kyn with pirfenidone augments anti-fibrotic efficacy.
Impact: Uncovers an endogenous immunometabolic circuit that restrains profibrotic macrophage states and offers a concrete, druggable pathway (AhR–SLC39A10–Zn2+) to enhance current PF therapy.
Clinical Implications: Suggests biomarker-guided adjunctive strategies: augmenting AhR–Zn2+ signaling or supplementing Kyn could synergize with pirfenidone; cautions that drug–metabolite interactions (pirfenidone suppressing Kyn) may modulate efficacy.
Key Findings
- PF patients show elevated serum Kyn, Trp, and KTR inversely correlated with lung function.
- Macrophage-specific Ido1 or AhR deletion exacerbates bleomycin-induced fibrosis; exogenous Kyn ameliorates it.
- Kyn activates AhR to induce Slc39a10, increasing intracellular Zn2+ and inhibiting profibrotic macrophage differentiation; Kyn plus pirfenidone enhances therapeutic efficacy.
Methodological Strengths
- Multi-level approach: human serum metabolomics linked to genetic macrophage-specific deletions and bleomycin PF model
- Mechanistic validation via ChIP-seq demonstrating AhR-driven Slc39a10 transcription
Limitations
- Translational dosing and safety of Kyn supplementation and Zn2+ modulation in humans remain untested.
- Heterogeneity among PF etiologies may affect generalizability of the macrophage-centric mechanism.
Future Directions: Early-phase trials to test AhR agonism/Kyn supplementation with pirfenidone; validate SLC39A10–Zn2+ signatures as pharmacodynamic biomarkers across PF subtypes.
BACKGROUND: Pulmonary fibrosis (PF) is an irreversible and lethal lung disease characterized by progressive scarring lacking safe and effective treatment options. Recent studies have underscored the role of macrophage polarization in fibrotic progression, yet the role of kynurenine (Kyn), a metabolite of tryptophan (Trp), in macrophages during PF progression remains elusive. METHODS: Liquid Chromatography-tandem Mass Spectrometry (LC-MS) analysis was used to detect tryptophan metabolism changes in the serum of PF patients and control subjects. Macrophage-specific Ido1 or Ahr deletion mice was utilized to explored the role of Kyn in the bleomycin-induced fibrotic mouse model and ChIP sequence was employed to elucidate the mechanism by which Kyn inhibits pro-fibrotic macrophage activation. RESULTS: We identified Kyn, Trp levels and Kyn/Trp ratio (KTR) were notably elevated in the serum of patients with different types of PF and these alterations were inversely correlated with lung function. Although such elevation might appear pathogenic, our functional studies demonstrate that Kyn exerts protective effects in PF, akin to brain natriuretic peptide in heart failure. Macrophage-specific deletion of Ido1 or aryl hydrocarbon receptor (AhR, the receptor of Kyn) exacerbated bleomycin-induced PF, while exogenous Kyn supplementation mitigated disease severity. Mechanistically, Kyn bound to the AhR, facilitating its nuclear translocation, where it promoted Slc39a10 transcription to increase the intracellular levels of zinc ion, thereby inhibiting profibrotic macrophage differentiation. Intriguingly, pirfenidone was noted with high potency to suppress Kyn production and our studies demonstrated that administration of Kyn along with pirfenidone effectively enhanced the therapeutic efficacy against PF. CONCLUSIONS: In summary, these findings reveal a previously unrecognized Kyn-AhR-SLC39A10-Zn